Pilot study of bempegaldesleukin in combination with nivolumab in patients with metastatic sarcoma
oleh: Sandra P. D’Angelo, Allison L. Richards, Anthony P. Conley, Hyung Jun Woo, Mark A. Dickson, Mrinal Gounder, Ciara Kelly, Mary Louise Keohan, Sujana Movva, Katherine Thornton, Evan Rosenbaum, Ping Chi, Benjamin Nacev, Jason E. Chan, Emily K. Slotkin, Hannah Kiesler, Travis Adamson, Lilan Ling, Pavitra Rao, Shreyaskumar Patel, Jonathan A. Livingston, Samuel Singer, Narasimhan P. Agaram, Cristina R. Antonescu, Andrew Koff, Joseph P. Erinjeri, Sinchun Hwang, Li-Xuan Qin, Mark T. A. Donoghue, William D. Tap
| Format: | Article |
|---|---|
| Diterbitkan: | Nature Portfolio 2022-06-01 |
Deskripsi
The activity of PD-1 blockade in patients with sarcoma has been modest so far. Here, the authors report the results of a pilot clinical trial to assess the efficacy and safety of bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, in combination with the PD1 blockade (nivolumab) in patients with locally advanced or metastatic high-grade sarcoma.